Compare Tango Therapeutics Inc. (TNGX) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Western Alliance Bancorporation — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B), while Western Alliance Bancorporation trades at $72.03 (market cap $7.88B). The key difference: Western Alliance Bancorporation is far larger — about 2.1× Tango Therapeutics Inc.'s market cap, and Western Alliance Bancorporation pays a 2.33% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Western Alliance Bancorporation for 3 Days on average.
| TNGX | WAL | |
|---|---|---|
Market Cap | $3.74B | $7.88B |
Volume | 3,438,781 | 1,680,725 |
Sector | Health | Financials |
52-Week High | $32.90 | $96.08 |
52-Week Low | $7.50 | $66.70 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $2.76B | $9.40B |
Dividend Yield | — | 2.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Western Alliance Bancorporation (WAL) trades at $73.73, down 1.29% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 8.15 and net income margin of 25.43%, while Q2 2026 earnings matched expectations. Recent news highlights institutional buying and the launch of WA VenueX platform. Analyst consensus remains strongly bullish with a $85.09 price target representing 15% upside potential.
WAL presents a compelling value opportunity with attractive valuation metrics and strong profitability, though technical indicators suggest near-term weakness. The primary risk involves banking sector regulatory changes, while institutional accumulation and positive earnings trajectory support the bullish case for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
